The study demonstrates that activating the vitamin D receptor (VDR) with calcitriol suppresses cell proliferation in pulmonary arterial smooth muscle cells, potentially reducing disease severity in pulmonary arterial hypertension (PAH).
Redalpine closes $200M fund; A base editing pact in China; Merck starts another Phase 3 for Imago drug
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
August 28, 2024